Clinicopathological characteristics and outcome of 31 patients with ETV6-NTRK3 fusion gene confirmed (mammary analogue) secretory carcinoma of salivary glands

Boon, Elles M. J.; Valstar, Matthijs H.; Graaf, Winette T.A. van der; Bloemena, Elisabeth; Willems, Stefan M.; Meeuwis, Cees A.; Slootweg, Pieter J.; Smit, Laura A.; Merkx, M.A.W.; Takes, Robert P.; Kaanders, J.H.A.M.; Groenen, Patricia J.T.A.; Flucke, Uta; Herpen, Carla M.L. van

doi:10.1016/j.oraloncology.2018.04.022

Cited by 59 publications

(62 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The prognostic value of biomarkers for parotid cancers has been investigated by several researchers, these biomarkers can not only predict the survival of parotid cancers but also exert in uence on treatment decisions [29,30]. What's more, these biomarkers might be attractive therapeutic targets in patients with parotid cancers, and the prognosis associated biomarkers will further enrich the clinical prognostic model, whereas our model needs further validation to con rm how much additional prognostic information could be derived from its use.…”

Section: Discussionmentioning

confidence: 95%

Prognostic Score and Associations With Survival Improvement Offered by Radiotherapy After Surgery for Adenocarcinomas of Parotid Gland: A Population-based Longitudinal Cohort Study

Qiu¹,

Zhang²

2020

Preprint

View full text Add to dashboard Cite

Background: Radiotherapy (RT) after surgery is a treatment option in the management of parotid adenocarcinoma, and the role of adjuvant RT for parotid adenocarcinoma remains to be clarified. The survival benefit of postoperative radiotherapy (PORT) based on prognostic risk factors needs further determination.Materials and methods: In this retrospective cohort study using SEER data, patients were divided into surgery+RT (RT group) and surgery alone (non-RT group). A prognostic risk model was constructed to stratify patients based on the survival rate. We performed a Cox regression analysis with propensity score weighting to evaluate survival benefit between the two groups. Results: We identified 2223 eligible patients with parotid adenocarcinoma, 1449 (65.2%) in the RT group and 774 (34.8%) in the non-RT group. Overall, 674 cancer-specific deaths occurred over a median follow-up of 141 months, the overall survival (OS) of RT group was better than that of non-RT group in the weighted analysis (HR=0.656, 95% CI=0.487-0.882, P=0.005). Significant survival improvements in the RT group compared with the non-RT group were only observed in patients with high risk (HR=0.647, 95% CI=0.426-0.983, P=0.041). The survival benefit of RT was significantly correlated with prognostic risk stratification (P<.001).Conclusion: In this population-based study, the patient prognostic risk stratification for parotid adenocarcinoma is associated with the magnitude of survival improvement by RT after surgery, suggesting that this risk model could provide decision guidance on comprehensive treatment strategy.

show abstract

Section: Discussionmentioning

confidence: 95%

Prognostic Score and Associations With Survival Improvement Offered by Radiotherapy After Surgery for Adenocarcinomas of Parotid Gland: A Population-based Longitudinal Cohort Study

Qiu¹,

Zhang²

2020

Preprint

View full text Add to dashboard Cite

show abstract

“…The risk of local recurrence and lymph node metastasis is 15% and 20%, respectively. The risk of distant metastasis is around 5% and cases with high-grade transformation have a worse prognosis [35].…”

Section: Discussionmentioning

confidence: 99%

Secretory Carcinoma of the Parotid: Making the Correct Diagnosis of a Rare Salivary Gland Carcinoma When Molecular Biology Testing Is Not Available

Montalvo

Galarza

Redrobán

2019

Case Reports in Pathology

View full text Add to dashboard Cite

Secretory carcinoma (SC) is a recently described entity occurring in the salivary glands. Before its description, SC was frequently classified as acinic cell carcinoma (ACC) or adenocarcinoma, not otherwise specified. Its particular histopathological and immunohistochemical characteristics are reminiscent of breast secretory carcinoma. Moreover, it displays a characteristic t(12;15) (p13;q25) translocation that results in the ETV6-NTRK3 gene fusion. This translocation has not been reported in any other salivary gland carcinoma. Identification of the t(12;15) (p13;q25) translocation is the gold standard for diagnosis, although some cases that do not present this specific translocation have already been reported. In such cases, diagnosis is challenging. In addition, some diagnostic pathology laboratories lack the resources to perform the molecular analysis to diagnose SC. In this scenario, morphology and immunohistochemistry are fundamental. Therefore, we report a case emphasizing the typical morphology of SC and its immunochemical profile to establish a final diagnosis without molecular biology tests. This case aims to demonstrate the importance of recognizing the typical presentation of a rare tumor so that clinicians will be informed or reminded of it and consider this entity among the differential diagnoses, when necessary. Moreover, in low-resource settings where molecular analysis is not available, being familiar enough with the histology of this tumor and using the immunoprofile as a key tool for differential diagnosis would be of great importance in establishing the correct diagnosis. The differential diagnosis includes, above all, acinic cell carcinoma and other salivary neoplasms such as intraductal carcinoma, low-grade mucoepidermoid carcinoma, and adenocarcinoma, not otherwise specified, which is actually a rule-out diagnosis.

show abstract

“…MASC is usually a non‐tender, slow‐growing lesion with size ranging from 1 to 4 cm . Parotid gland is the most common salivary gland involved . Second most common is submandibular gland.…”

mentioning

confidence: 99%

“…MASC shows chromosomal translocation t(12,15) (p13;q25), which results in the fusion of the ETV6 and NTRK3 genes . However, this translocation is not explicit for MASC and can be seen in other neoplasms, including secretory breast carcinoma, congenital mesoblastic nephroma and infantile fibrosarcoma . Other described tumours are not seen in the salivary gland region; therefore, this mutation helps in the diagnosis of MASC.…”

mentioning

confidence: 99%

Secretory carcinoma: Fine needle aspiration cytology of a rare parotid gland tumour

et al. 2020

View full text Add to dashboard Cite

show abstract

Clinicopathological characteristics and outcome of 31 patients with ETV6-NTRK3 fusion gene confirmed (mammary analogue) secretory carcinoma of salivary glands

Abstract: The clinical course of SC is favorable with a low rate of locoregional recurrence and excellent survival. Given the low incidence of nodal metastases, elective neck treatment, i.e. surgery and/or radiotherapy, does not seem to be indicated.

Cited by 59 publications

References 16 publications

Prognostic Score and Associations With Survival Improvement Offered by Radiotherapy After Surgery for Adenocarcinomas of Parotid Gland: A Population-based Longitudinal Cohort Study

Prognostic Score and Associations With Survival Improvement Offered by Radiotherapy After Surgery for Adenocarcinomas of Parotid Gland: A Population-based Longitudinal Cohort Study

Secretory Carcinoma of the Parotid: Making the Correct Diagnosis of a Rare Salivary Gland Carcinoma When Molecular Biology Testing Is Not Available

Secretory carcinoma: Fine needle aspiration cytology of a rare parotid gland tumour

Contact Info

Product

Resources

About